Oragenics designates 8M Series F Convertible Preferred Stock for Odyssey asset purchase

ORAGENICS INC

Filed Certificate of Designation for 8,000,000 shares of Series F Convertible Preferred Stock for the Odyssey Health asset purchase.
Series F is economically equivalent to common stock; liquidation junior to Class A, B, and Series E Preferred; no dividends, no voting rights.
Converts 1:1 into common stock upon close of Odyssey purchase, subject to shareholder approval for issuance and 350M authorized share increase.
Conversion capped at 19.9% of outstanding common stock until NYSE American listing or delisting and change-of-control approval if needed.
Redemption not permitted; no trading market expected; preemptive rights not provided.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ORAGENICS INC: Filed Certificate of Designation establishing Series F Convertible Preferred Stock (effective 2023-12-04).

Change: charter amendment
Effective: 2023-12-04

Exact text from the filing

On December 4, 2023, in anticipation of the the Odyssey Asset Purchase, the Company filed a Certificate of Designation with the Secretary of State for the State of Florida (the “ Certificate of Designation ”) designating 8,000,000 shares out of the authorized but unissued shares of its preferred stock as Series F Convertible Preferred Stock.

View on SEC.gov

59 governance changes filed in the last 30 days. Browse all governance changes →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-23-044220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.